A high-fat and cholesterol diet causes fatty liver in guinea pigs. the role of iron and oxidative damage

Free Radical Research

Volumn 47, Issue 8, 2013, Pages 602-613

  Ye, P ^a   Cheah, I K ^a   Halliwell, B ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cholesterol; Dietary supplementation; Iron metabolism; Lipid peroxidation; Non alcoholic fatty liver disease

Indexed keywords

CARBONYL DERIVATIVE; CHOLESTEROL; FERRITIN; HEMOSIDERIN; HEPCIDIN; IRON; ISOPROSTANE DERIVATIVE; LIPID; TRANSFERRIN; TRANSFERRIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL DIET; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; EXPERIMENTAL GUINEA PIG; INTESTINE ABSORPTION; IRON ABSORPTION; IRON BLOOD LEVEL; LIPID DIET; LIPID LIVER LEVEL; LIPID PEROXIDATION; LIVER HISTOLOGY; LIVER INJURY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN BLOOD LEVEL;

ANIMALS; BIOLOGICAL MARKERS; CHOLESTEROL, DIETARY; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; GUINEA PIGS; IRON; LIPID PEROXIDATION; LIVER; MALE; OXIDATIVE STRESS;

EID: 84880565780     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2013.806796     Document Type: Article

References (47)

1. Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 2011;48:97-113.
2. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab 2008;93:S74-80.
3. O'Brien J, Powell LW. Non-alcoholic fatty liver disease: is iron relevant? Hepatol Int 2012; 6: 332-341.
4. Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lutjohann D, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic infl ammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008; 48: 474-486.
5. Subramanian S, Goodspeed L, Wang S, Kim J, Zeng L, Ioannou GN, et al. Dietary cholesterol exacerbates hepatic steatosis and infl ammation in obese LDL receptor-defi cient mice. J Lipid Res 2011;52:1626-1635.
6. Kratz M. Dietary cholesterol, atherosclerosis and coronary heart disease. Handb Exp Pharmacol 2005:195-213.
7. Harris JR, Milton NG. Cholesterol in Alzheimer's disease and other amyloidogenic disorders. Subcell Biochem 2010;51:47-75.
8. Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the signifi cance of dietary cholesterol. Scand J Gastroenterol 2009;44:471-477.
9. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011;55:920-932.
10. Halliwell B, Gutteridge JMC. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984;219:1-14.
11. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-1109.
12. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fi brosis. Gastroenterology 1998;114:311-318.
13. Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol Res 2009; 39: 213-222.
14. Graham RM, Chua AC, Carter KW, Delima RD, Johnstone D, Herbison CE, et al. Hepatic iron loading in mice increases cholesterol biosynthesis. Hepatology 2010;52:462-471.
15. Morrow JD, Chen Y, Brame CJ, Yang J, Sanchez SC, Xu J, et al. The isoprostanes: unique prostaglandin-like products of free-radical-initiated lipid peroxidation. Drug Metab Rev 1999;31:117-139.
16. Halliwell B, Lee CY. Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxid Redox Signal 2010;13:145-156.
17. Tang SY, Whiteman M, Peng ZF, Jenner A, Yong EL, Halliwell B. Characterization of antioxidant and antiglycation properties and isolation of active ingredients from traditional Chinese medicines. Free Radic Biol Med 2004; 36: 1575-1587.
18. Langford MP, Redens TB, Harris NR, Lee S, Jain SK, Reddy S, McVie R. Plasma levels of cell-free apoptotic DNA ladders and gamma- glutamyltranspeptidase (GGT) in diabetic children. Exp Biol Med (Maywood) 2007;232:1160-1169.
19. Szasz G. A kinetic photometric method for serum gammaglutamyl transpeptidase. Clin Chem 1969; 15: 124-136.
20. Riemer J, Hoepken HH, Czerwinska H, Robinson SR, Dringen R. Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal Biochem 2004;331:370-375.
21. Sinclair PR, Gorman N, Jacobs JM. Measurement of heme concentration. Curr Protoc Toxicol 2001 ;Chapter 8:Unit 8 3.
22. Jenner A, Ren M, Rajendran R, Ning P, Huat BT, Watt F, Halliwell B. Zinc supplementation inhibits lipid peroxidation and the development of atherosclerosis in rabbits fed a high cholesterol diet. Free Radic Biol Med 2007; 42: 559-566.
23. Lee CY, Huang SH, Jenner AM, Halliwell B. Measurement of F 2-isoprostanes, hydroxyeicosatetraenoic products, and oxysterols from a single plasma sample. Free Radic Biol Med 2008;44:1314-1322.
24. Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961;93:440-447.
25. Ye P, Cheah IK, Halliwell B. High fat diets and pathology in the guinea pig. Atherosclerosis or liver damage? Biochim Biophys Acta 2013;1832:355-364.
26. Cook RP, Thomson RO. Cholesterol metabolism. 3. Cholesterol metabolism in the guinea pig and rabbit. Biochem J 1951;49:72-77.
27. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
28. Bugianesi E, Manzini P, D ' Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fi brosis in nonalcoholic fatty liver. Hepatology 2004;39:179-187.
29. Chevion M, Berenshtein E, Stadtman ER. Human studies related to protein oxidation: protein carbonyl content as a marker of damage. Free Radic Res 2000; 33: S99-108.
30. Tsushima Y, Endo K. Spleen enlargement in patients with nonalcoholic fatty liver: correlation between degree of fatty infi ltration in liver and size of spleen. Dig Dis Sci 2000;45:196-200.
31. Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA 2001;98:8160-8162.
32. Andrews NC. Closing the iron gate. N Engl J Med 2012;366:376-377.
33. Nagashima M, Kudo M, Chung H, Ishikawa E, Hagiwara S, Nakatani T, Dote K. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Hepatol Res 2006;36:288-293.
34. Fujita N, Sugimoto R, Motonishi S, Tomosugi N, Tanaka H, Takeo M, et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol 2008;49:702-710.
35. Bridle K, Cheung TK, Murphy T, Walters M, Anderson G, Crawford DG, Fletcher LM. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 2006;30:106-112.
36. Potter BJ, Chapman RW, Nunes RM, Sorrentino D, Sherlock S. Transferrin metabolism in alcoholic liver disease. Hepatology 1985; 5: 714-721.
37. Bothwell TH, MacPhail AP. Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Semin Hematol 1998;35:55-71.
38. Le Lan C, Loreal O, Cohen T, Ropert M, Glickstein H, Laine F, et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005;105:4527-4531.
39. Shin DY, Chung J, Joe Y, Pae HO, Chang KC, Cho GJ, et al. Pretreatment with CO-releasing molecules suppresses hepcidin expression during infl ammation and endoplasmic reticulum stress through inhibition of the STAT3 and CREBH pathways. Blood 2012;119:2523-2532.
40. Otogawa K, Kinoshita K, Fujii H, Sakabe M, Shiga R, Nakatani K, et al. Erythrophagocytosis by liver macrophages (Kupff er cells) promotes oxidative stress, infl ammation, and fi brosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol 2007;170:967-980.
41. Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O, et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 2008;87:1374-1383.
42. Hoff man KE, Yanelli K, Bridges KR. Ascorbic acid and iron metabolism: alterations in lysosomal function. Am J Clin Nutr 1991;54:1188S-1192S.
43. O ' Connell M, Halliwell B, Moorhouse CP, Aruoma OI, Baum H, Peters TJ. Formation of hydroxyl radicals in the presence of ferritin and haemosiderin. Is haemosiderin formation a biological protective mechanism? Biochem J 1986;234:727-731.
44. Lecube A, Hernandez C, Simo R. Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload. Diabetes Metab Res Rev 2009;25:403-410.
45. Facchini FS, Hua NW, Stoohs RA. Eff ect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002;122:931-939.
46. Davis RJ, Corvera S, Czech MP. Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J Biol Chem 1986;261:8708-8711.
47. Tsuchiya H, Ebata Y, Sakabe T, Hama S, Kogure K, Shiota G. High-fat, high-fructose diet induces hepatic iron overload via a hepcidin-independent mechanism prior to the onset of liver steatosis and insulin resistance in mice. Metabolism 2013;62:62-69.